Sather Financial Group Inc grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,051 shares of the company’s stock after purchasing an additional 399 shares during the quarter. Sather Financial Group Inc’s holdings in Johnson & Johnson were worth $1,341,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Financial Gravity Wealth Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $105,000. WP Advisors LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $108,000. FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $117,000. Fusion Family Wealth LLC increased its position in shares of Johnson & Johnson by 621.4% in the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after buying an additional 870 shares in the last quarter. Finally, Live Your Vision LLC increased its position in shares of Johnson & Johnson by 58.3% in the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares in the last quarter. 66.06% of the stock is currently owned by institutional investors.
In other news, CEO Alex Gorsky sold 264,465 shares of the stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the completion of the transaction, the chief executive officer now directly owns 481,254 shares in the company, valued at approximately $70,243,833.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joaquin Duato sold 40,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now owns 112,848 shares of the company’s stock, valued at $16,290,737.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 320,805 shares of company stock valued at $46,684,507. Company insiders own 0.22% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.90 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.53%. Johnson & Johnson’s dividend payout ratio is 49.32%.
JNJ has been the subject of a number of recent analyst reports. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Tuesday, November 20th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 14th. Citigroup upped their price objective on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Finally, Raymond James upped their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $143.97.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/26/sather-financial-group-inc-has-1-34-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.